title: Tolerability of initiation doses of once-monthly paliperidone palmitate in patients with recently diagnosed schizophrenia in an acute treatment trial.
abstract: OBJECTIVE
  To examine the tolerability of the recommended initiation doses for once-monthly injectable paliperidone palmitate in patients who have recently been diagnosed with schizophrenia and for whom high doses may pose tolerability concerns.
  
  
  METHODS
  A post hoc analysis from a 13-week double-blind study of patients with schizophrenia randomized 1:1:1:1 to placebo or paliperidone palmitate at 25, 100, or 150 mg equivalents (mg eq) of paliperidone (corresponding to 39, 156, or 234 mg respectively). This analysis focused on the recently diagnosed subgroup (≤5 years; N = 146) who received the recommended initiation dosage of paliperidone palmitate [150 mg eq on day 1 (n = 109) followed by 100 mg eq on day 8 (n = 39)] or placebo (n = 37). Adverse events (AEs), reported in ≥2% of patients receiving paliperidone palmitate during days 1-7 or ≥5% during days 8-36, and in a higher percentage of patients receiving paliperidone palmitate than placebo, were identified. AE relative risks (RRs) and 95% confidence intervals (CIs) were determined. A RR was considered potentially significant when its 95% CI did not include 1.
  
  
  RESULTS
  Overall, day 1-7 AE rates were 37.6% (41 of 109) and 29.7% (11 of 37) with paliperidone palmitate and placebo respectively; injection site pain (5.5% versus 2.7%, RR 2.0; 95% CI 0.25 to 16.37), agitation (4.6% versus 2.7%; RR 1.7; 95% CI 0.21 to 14.06), and headache (3.7% versus 0.0%; RR 3.1; 95% CI 0.17 to 56.41) met the ≥2% criteria. Day 8-36 AE rates were 41.0% (16 of 39) and 37.8% (14 of 37) with paliperidone palmitate and placebo respectively; anxiety (5.1% versus 0.0%; RR 4.8; 95% CI 0.24 to 95.76) met the ≥5% criteria. Key limitations were that some patients may have been ill for a significant time before formal diagnosis and that the number of patients is low in this subgroup, limiting the ability to detect statistical significance for AE RRs.
  
  
  CONCLUSIONS
  Paliperidone palmitate initiation doses (150 mg eq day 1, 100 mg eq day 8) were tolerated in this subgroup of patients who were recently diagnosed with schizophrenia, with no unexpected findings. Although the same size was small, these data identified AEs that may be encountered during the week and month after initiation dosing. These findings may assist clinicians when paliperidone palmitate is considered an appropriate treatment choice for these patients.
authors: Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville, New Jersey, USA.
authors: Cynthia A
authors: CA
authors: Bossie
authors: Dong-Jing
authors: DJ
authors: Fu
authors: Jennifer Kern
authors: JK
authors: Sliwa
authors: Yi-Wen
authors: YW
authors: Ma
authors: Larry
authors: L
authors: Alphs
keywords: paliperidone palmitate; recent diagnosis; schizophrenia; tolerability; treatment
references: Am J Psychiatry. 2005 May;162(5):947-53
references: 15863797
references: Schizophr Bull. 1993;19(1):71-84
references: 8451614
references: J Psychopharmacol. 2005 Sep;19(5 Suppl):5-14
references: 16144781
references: Acta Psychiatr Scand. 2002 Oct;106(4):286-90
references: 12225495
references: Am J Psychiatry. 1999 Jan;156(1):79-87
references: 9892301
references: CNS Drugs. 2009 Oct;23(10):837-55
references: 19739694
references: Am J Psychiatry. 2004 Apr;161(4):692-9
references: 15056516
references: J Clin Psychiatry. 2009 Oct;70(10):1397-406
references: 19906343
references: Schizophr Res. 2007 Feb;90(1-3):147-61
references: 17092691
references: J Clin Psychiatry. 2003 Nov;64(11):1308-15
references: 14658944
references: Psychiatr Serv. 2003 May;54(5):719-23
references: 12719504
references: CNS Drugs. 2007;21(6):441-8
references: 17521224
references: Lancet. 2004 Jun 19;363(9426):2063-72
references: 15207959
references: Int J Clin Pract. 2007 Aug;61(8):1356-70
references: 17627711
references: Schizophr Bull. 2001;27(4):563-70
references: 11824483
references: Eur Psychiatry. 2002 May;17(3):129-38
references: 12052573
references: Am J Psychiatry. 2004 Jan;161(1):160-3
references: 14702266
references: Prog Neuropsychopharmacol Biol Psychiatry. 2008 Jul 1;32(5):1231-5
references: 18442879
references: Curr Med Chem. 2004 Feb;11(3):343-58
references: 14965236
references: Prog Neuropsychopharmacol Biol Psychiatry. 2003 May;27(3):473-81
references: 12691783
references: J Clin Psychopharmacol. 2010 Jun;30(3):235-44
references: 20473057
references: Schizophr Res. 2009 May;110(1-3):1-23
references: 19328655
references: J Am Acad Child Adolesc Psychiatry. 2001 May;40(5):504-5
references: 11349691
references: World Psychiatry. 2008 Oct;7(3):148-56
references: 18836582
references: Biol Psychiatry. 2007 Dec 15;62(12):1363-70
references: 17601495
references: J Child Adolesc Psychopharmacol. 1999;9(4):239-45
references: 10630453
references: Med J Aust. 2007 Oct 1;187(S7):S8-10
references: 17908033
references: J Psychiatr Res. 2004 Mar-Apr;38(2):163-8
references: 14757330
references: Early Interv Psychiatry. 2010 Feb;4(1):64-78
references: 20199482
references: Am J Psychiatry. 2005 Oct;162(10):1785-804
references: 16199825
references: Neuropsychopharmacology. 2010 Sep;35(10):2072-82
references: 20555312
references: Br J Psychiatry. 2008 Sep;193(3):203-9
references: 18757977
references: Arch Gen Psychiatry. 1999 Mar;56(3):241-7
references: 10078501
references: Schizophr Res. 2010 Feb;116(2-3):107-17
references: 19959339
references: Br J Psychiatry Suppl. 2005 Aug;48:s120-4
references: 16055801
references: Schizophr Res. 1991 Oct;5(3):201-2
references: 1684719
references: Psychol Med. 2003 Jan;33(1):97-110
references: 12537041
references: J Clin Psychiatry. 2002 Oct;63(10):885-91
references: 12416598
references: Curr Med Res Opin. 2010 Feb;26(2):377-87
references: 20001492
references: J Am Board Fam Pract. 2001 Jul-Aug;14(4):278-82
references: 11458971
references: Biol Psychiatry. 2001 Dec 1;50(11):884-97
references: 11743943
references: Prog Neuropsychopharmacol Biol Psychiatry. 2009 Aug 31;33(6):1022-31
references: 19481579
references: J Clin Psychiatry. 2001;62 Suppl 7:22-31
references: 11346192
references: J Clin Psychiatry. 1999;60 Suppl 23:5-9
references: 10625193
references: J Clin Psychopharmacol. 2008 Apr;28(2):210-3
references: 18344732
references: Schizophr Res. 2010 Jun;119(1-3):1-10
references: 20347270
references: Psychiatr Serv. 2008 May;59(5):487-96
references: 18451003
references: J Child Adolesc Psychopharmacol. 2001 Winter;11(4):389-94
references: 11838821
references: J Am Acad Child Adolesc Psychiatry. 2002 Dec;41(12):1439-46
references: 12447030
references: CNS Drugs. 2008;22(7):547-62
references: 18547125
references: Arch Gen Psychiatry. 2005 Sep;62(9):975-83
references: 16143729
references: Schizophr Bull. 1996;22(2):271-82
references: 8782286
references: J Clin Psychopharmacol. 2007 Feb;27(1):6-14
references: 17224706
references: Schizophr Res. 2007 Jul;93(1-3):117-30
references: 17466492
references: Acta Psychiatr Scand Suppl. 1994;382:11-5
references: 7916523
references: Drugs. 2005;65(8):1113-38
references: 15907146
references: Schizophr Bull. 2004;30(2):255-64
references: 15279044